Eiger BioPharmaceuticals Inc represents innovation, dedication, and excellence in the biopharmaceutical industry. Founded on the principle of advancing novel therapies for rare and ultra-rare diseases, Eiger BioPharmaceuticals Inc is committed to improving patients' lives by developing cutting-edge treatments. The company's corporate philosophy revolves around scientific rigor, collaboration, and patient-centered focus. Eiger BioPharmaceuticals Inc's unwavering commitment to scientific integrity and breakthrough innovations drives their mission to bring transformative medicines to patients globally. With a focus on meeting unmet medical needs, Eiger BioPharmaceuticals Inc continues to push boundaries in drug development, making it a leader in the biopharmaceutical sector.

Eiger BioPharmaceuticals Inc primarily operates in the United States. The company is based in Palo Alto, California and focuses on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases. With a strong presence in the U.S. healthcare sector, Eiger BioPharmaceuticals Inc operates within the dynamic and innovative biotechnology industry. Their dedication to finding solutions for unmet medical needs has positioned them as a prominent player in the U.S. market.

Eiger BioPharmaceuticals Inc has achieved several significant milestones. The company successfully completed a Phase 2 ULTRA clinical study for Lonafarnib in Hepatitis Delta Virus (HDV) infection, demonstrating positive results. Furthermore, Eiger initiated Phase 3 D-LIVR study evaluating Lonafarnib in HDV patients, displaying its commitment to advanced treatments. Additionally, the company received Breakthrough Therapy Designation from the FDA for its drug Avexitide in Post-Bariatric Hypoglycemia, acknowledging its potential to fill an unmet medical need. Eiger BioPharmaceuticals Inc continues to make strides in developing innovative therapies and improving patient outcomes in various disease areas.

Eiger BioPharmaceuticals Inc is a pharmaceutical company specializing in the development of targeted therapies for rare diseases. Founded in 2008, the company is headquartered in Palo Alto, California. Eiger BioPharmaceuticals focuses on developing innovative treatments for diseases such as Hepatitis Delta Virus (HDV) infection, which currently has no approved therapies. With a dedicated team of scientists and researchers, Eiger BioPharmaceuticals has made significant progress in advancing potential breakthrough treatments and has successfully conducted various clinical trials. The company's commitment to addressing unmet medical needs and their expertise in rare diseases make them a key player in the biopharmaceutical industry.

The main competitors of Eiger BioPharmaceuticals Inc in the market are companies like Gilead Sciences, Vertex Pharmaceuticals, and Intercept Pharmaceuticals.

Eiger BioPharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

Eiger BioPharmaceuticals Inc's business model focuses on developing and commercializing innovative therapies for rare and ultra-rare diseases. The company aims to address unmet medical needs and improve the lives of patients with limited treatment options. Eiger BioPharmaceuticals primarily focuses on developing targeted therapies that modulate the underlying disease pathways, aiming to provide safe and effective treatment options. With a strong emphasis on research and development, the company collaborates with leading academic institutions and partners to advance its pipeline of potential therapies. By leveraging its expertise in drug discovery and development, Eiger BioPharmaceuticals aims to bring novel treatments to market and make a positive impact in the healthcare industry.

مُعامل القيمة السوقية إلى الأرباح لـ Eiger BioPharmaceuticals هو ؜-٠٫٧٥.

مُعامِل القيمة إلى المبيعات Eiger BioPharmaceuticals هو ٠٫٦٩.

نقاط جودة AlleAktien لـ Eiger BioPharmaceuticals هي 5/10.

المتوقعة Eiger BioPharmaceuticals الإيرادات هي ٢٥٫٧٢ مليون. USD.

صافي الربح المتوقعة Eiger BioPharmaceuticals هو ؜-٢٣٫٥٥ مليون. USD.

Eiger BioPharmaceuticals Inc is a biotechnology company focused on the development and commercialization of innovative therapies. The company specializes in developing therapies for rare and life-threatening diseases that have no adequate treatment. Its business model is based on the discovery, development, and marketing of novel therapeutic products. It currently focuses on developing therapies in four different areas specializing in rare and life-threatening diseases: Hepatitis Delta (HDV), Pulmonary Arterial Hypertension (PAH), Lysosomal Storage Diseases (LSD), and COVID-19. The company has its own clinical development organization and proprietary technology called EigerOneTM. Eiger BioPharmaceuticals invests in research and development, holds patents and intellectual property, and has an international presence and partnerships to accelerate research efforts. Overall, its goal is to provide innovative solutions for patients with rare and life-threatening diseases.

يوزع Eiger BioPharmaceuticals أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Eiger BioPharmaceuticals في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـEiger BioPharmaceuticals هو US28249U1051.

رمز WKN لـ Eiger BioPharmaceuticals هو A2AF9X.

الرمز المُختصر لـ Eiger BioPharmaceuticals هو EIGR.

خلال آخر 12 شهراً، دفعت Eiger BioPharmaceuticals توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Eiger BioPharmaceuticals خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Eiger BioPharmaceuticals هي .

Eiger BioPharmaceuticals يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Eiger BioPharmaceuticals دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Eiger BioPharmaceuticals يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Eiger BioPharmaceuticals المُعلن عنها في ٤‏/٧‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٤‏/٧‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ٤‏/٧‏/٢٠٢٤.

في العام 2023، وزعت Eiger BioPharmaceuticals 0 USD كأرباح أسهم.

يتم توزيع أرباح Eiger BioPharmaceuticals بالعملة USD.